Attempts to optimize outcomes in cord blood transplantation (CBT) by using new conditioning regimens and standardization of cord blood unit selection are warranted. In all, 88 patients (18 children and 70 adults) with hematological malignancy from nine Spanish institutions underwent a single-unit CBT after an i.v. BU-based myeloablative conditioning regimen. All evaluable patients except one engrafted. The overall cumulative incidence (CI) of myeloid engraftment was 94% at a median time of 19 days. In multivariate analysis, nonadvanced disease stage was the only factor with a favorable impact on myeloid engraftment. The CI of acute GVHD grades II --IV and chronic extensive GVHD were 24% each. The CI of nonrelapse mortality at 100 days, 180 days and 5 years was 14, 23 and 44%, respectively. The 5-year CI of relapse was 18%, whereas disease-free survival (DFS) was 46%, 39% and 11% for patients transplanted in early, intermediate and advanced stages of the disease, respectively. Our study shows high rates of engraftment with fast neutrophil recovery in patients undergoing single-unit CBT using a BU-based conditioning regimen. Long-term DFS can be achieved in a substantial number of patients with high-risk hematological malignancies, particularly when transplanted in an early stage of the disease.
INTRODUCTION
Umbilical cord blood (UCB) has emerged as an alternative stem cell source for patients in need of hematopoietic allo-SCT who lack an HLA-matched adult donor. 1 However, its widespread use in adults is limited because of slow hematological recovery, substantial rates of graft failure and early nonrelapse mortality (NRM). 2 To overcome this drawback, various strategies, including use of two double-cord blood units double, 3 coinfusion of PBSCs, 4 ex vivo expansion 5 and intrabone infusion, 6 have been designed. To date, none of these new approaches has shown clear benefits for the patient's outcome compared with using a single unmanipulated cord blood unit.
There have been a few attempts to use new conditioning regimens and standardize cord blood unit selection to optimize engraftment, improve anti-leukemic efficacy and minimize toxicity. Preliminary data using a modification of the classic schedule BU --CY intensified with thiotepa and anti-thymocyte globulin (ATG) suggested a fast and high rate of engraftment. 7 Since then, a reduced-toxicity conditioning regimen with once-daily i.v. infusion of BU and fludarabine has been reported. 8 In an effort to reduce early mortality, we designed a conditioning regimen with i.v. BU, thiotepa, fludarabine and ATG for patients undergoing UCB transplantation from an unrelated donor.
Here we report the outcome of a series of patients with a hematological malignancy who received a single-unit UCB transplant from an unrelated donor using a chemotherapy-based myeloablative conditioning regimen. The aims of the study were to evaluate the safety and efficacy of the procedure after longterm follow-up and to identify variables that influenced the shortand long-term outcomes.
PATIENTS AND METHODS

Eligibility criteria
Between March 2005 and February 2008, 88 consecutive patients with hematological malignancies underwent UCB transplantation from an unrelated donor at nine different institutions within the GETH (Grupo Españ ol de Trasplante Hematopoyé tico y Terapia Celular). Patients were eligible for enrollment if they met the following criteria: (i) high-risk hematological malignancy requiring urgent hematopoietic cell transplantation; (ii) absence of a suitable related donor (HLA identical or one-Ag mismatched); (iii) lack of an HLA-identical unrelated donor after searching in the international registries; and (iv) an available UCB unit fulfilling the minimum established criteria for HLA compatibility and prefreezing cell dose. The UCB unit had 44/6 HLA matched with the recipient. The HLA class I Ags (A and B) were determined using serologic or low-resolution DNA typing and class II Ags (DRB1) using high-resolution DNA typing. The following cell doses were required: total nucleated cells (TNCs) The institutional review board approved the protocol, and written informed consent was obtained from all the patients according to the Declaration of Helsinki.
Conditioning regimen
All patients received the myeloablative conditioning regimen comprising thiotepa 5 mg/kg/day on days À7 and À6, i.v. BU 3.2 mg/kg/day as a single daily dose on days À5 to À3, fludarabine 50 mg/m 2 /day on days À5 to À3 and rabbit ATG (Thymoglobulin, Sangstat/Genzyme, Lyon, France) 2 mg/ kg/day on days À5 to À2. The BU dose was adjusted in patients weighing o34 kg to achieve a total dose of 12, 14.4, 13.2 and 11.4 mg/kg in patients weighing o9, 9 --16, 17 --23 and 24 --34 kg, respectively. GVHD management GVHD prophylaxis comprised CYA 1.5 mg/kg/12 h i.v., followed by 3 --5 mg/ kg/12 h orally when oral intake was possible, with a slow tapering starting between day þ 90 and þ 180 to discontinue on day þ 180 or before if feasible. CYA was combined with prednisone 0.5 mg/kg/day on days þ 7 to þ 14 and 1 mg/kg/day on days þ 14 to þ 28, with slow tapering to discontinue on day þ 180 in adults or day þ 90 in patients o14 years.
Patients who developed acute GVHD received first-line therapy with methylprednisolone at doses ranging from 2 to 20 mg/kg/day followed by gradual tapering, according to institutional policy. Chronic GVHD was treated with prednisone 1 mg/kg/day.
Supportive care
Patients were nursed in HEPA-filtered rooms. Prophylaxis of BU-induced neurologic toxicity with diphenylhydantoin, clonazepam or lorazepam was administered according to the current protocols at each site.
G-CSF was administered s.c. at 5 mg/kg/day from day þ 7 until neutrophil engraftment. Antibacterial and antifungal prophylaxis were given following institutional policies. Recommendations were made to dispense oral ciprofloxacin during neutropenia or until the start of broadspectrum antibiotics and a mold-active azole (itraconazole or voriconazole) until day þ 100 or whenever the patient was given steroid for the treatment of GVHD. Prophylaxis against Pneumocystis jiroveci comprised cotrimoxazole from day À10 to day À2, which was then restarted after engraftment on 2 days a week and maintained for a minimum of 1 year or until immunosuppressive therapy was stopped. Pentamidine was used if cotrimoxazole was contraindicated. All blood products were irradiated and leukocyte depleted. CMV-seropositive patients received high-dose acyclovir 500 mg/m 2 /8 h i.v. until neutrophil recovery. Thereafter, some institutions followed a preemptive approach with PCR monitoring, whereas others administered valganciclovir prophylactically as described previously. 9 Nonspecific Ig was administered i.v. at a dose of 500 mg/kg weekly until day þ 100 and then monthly during the first year after transplantation.
Definitions
Myeloid engraftment was defined as an ANC of 0.5. Â 10 9 /L for 3 or more consecutive days. Platelet engraftment was defined as a platelet count of 20 Â 10 9 /L or higher, without transfusion support, for 7 consecutive days. Patients who survived 428 days after transplantation and who failed to achieve myeloid engraftment were considered as graft failures. The time to myeloid or platelet engraftment was defined as the time required to reach the first day of engraftment. Secondary graft failure was defined as the loss of the engraftment. Full donor chimerism was defined as the presence of 495% donor hematopoiesis. Acute and chronic GVHD were defined and graded according to the standard criteria. 10 --12 Disease status at the time of transplantation was classified as follows: (i) early stage, acute leukemia and lymphoma in first CR (CR1), untreated myelodysplastic syndrome with o5% blasts and/or CML in the first chronic phase; (ii) intermediate stage, acute leukemia, lymphoma or myelodysplastic syndrome in a second or further CR and CML in a second chronic or accelerated phase; and (iii) advanced stage, acute leukemia and lymphoma not in remission, CML in blast crisis and untreated refractory anemia with excess blasts.
Statistical analysis
The probabilities of engraftment, NRM, GVHD and relapse were estimated by the cumulative incidence (CI) method (marginal probability). 13, 14 For CI analysis of engraftment, GVHD and relapse, death in CR was considered as a competing cause of failure, and for NRM, relapse was considered the competing event. Unadjusted time-to-event analyses were performed using the Kaplan --Meier estimate, 15 and, for comparisons, the log-rank tests. 16 Disease-free survival (DFS) was calculated from the date of UCB transplantation. In the analysis of DFS, relapse or death in CR, whichever occurred first, was considered an uncensored event. The variables considered for prognostic factor analysis were: age, sex, recipient body weight, recipient CMV serology, disease status at transplantation, previous auto-SCT, HLA compatibility considering low-resolution typing for class I and high-resolution typing for class II Ags, ABO blood group mismatch, donor --recipient sex match, and the numbers of TNCs and CD34 þ cells before freezing and infusion. Continuous variables were dichotomized at the most discriminative cutoff point for each outcome. Variables with a P-value o0.10 for each endpoint were tested in multivariate analysis using the Cox proportional hazard model for temporal events. 17 The follow-up of the patients was updated on 1 May 2011. All P-values reported are two-sided. Except for the CI method, computations were performed using the appropriate programs from the BMDP statistical library (BMDP Statistical Software, Los Angeles, CA, USA). 18 Table 1 shows the main characteristics of the 88 patients included in the study. Briefly, 45 patients were males and 43 females with a median age of 28 years (range 1 --52). In all, 72 (82%) patients were 414 years of age. In total, 47 (53%) cord blood recipients were transplanted in the early stage of the disease. Two patients had myelodysplastic syndrome with o5% blasts and a high International Prognostic Index score and were untreated at the time of transplantation. Two other patients had peripheral T-cell nonHodgkin's lymphoma with a high-risk International Prognostic Index score: one patient had gd s.c. panniculitis-like T-cell lymphoma stage IV that was refractory to CHOP chemotherapy and achieved CR1 after auto-SCT, and one patient with peripheral T-cell lymphoma stage IV achieved CR1 after salvage chemotherapy. All other patients who were transplanted in the early phase had acute leukemia in CR1. The median time from diagnosis to transplantation for patients transplanted in CR1 was 6 months (range 1 --14). In all, 16 patients had relapsed after a previous auto-SCT. The median follow-up for surviving patients was 55 months (range 8 --74). One patient who had relapsed and was evaluated for a second transplant at another institution was lost to follow-up after 8 months; all remaining patients had a follow-up 43 years.
RESULTS
Patient characteristics
Cord blood unit and transplant characteristics Table 2 shows the characteristics of the cord blood units and those related to the transplantation procedure.
In all, 8 (9%) patients received a fully matched UCB unit and 81 (91%) patients received an HLA-mismatched unit. Donor --recipient disparity in one and two out of the six Ags occurred in 36 (41%) and 44 (50%) patients, respectively. The median TNC and CD34 þ cell doses infused were 2.4 Â 10 7 (range 1.4 --32) and 1.4 Â 10 5 /kg (range 0.1 --31), respectively. In total, 27 (31%) patients received UCB units with a major ABO blood group mismatch.
Myeloid engraftment Three patients died on days 9, 11 and 19 after UCB infusion without evidence of myeloid engraftment: two because of bacterial infection and one because of multiorgan failure of unknown cause. Another patient died on post-transplant day 31 because of multiorgan failure with complete donor chimerism and with an ANC o0.5 Â 10 9 /L. One additional patient had a primary graft failure with autologous reconstitution. The remaining 83 patients experienced myeloid engraftment at a median time of 19 days (range 11 --44). The CI of myeloid engraftment at 44 days was 94% ( Figure 1 ). All patients with myeloid engraftment showed full donor chimerism at the time of reconstitution. One patient with neutrophil recovery on posttransplant day 18 subsequently lost the graft on post-transplantation day 51.
In the univariate analysis, the variables that influenced the time to myeloid engraftment were CMV serology of the recipient, disease status at transplantation, previous auto-SCT and a CD34 þ cell dose at infusion with a best cutoff at 1.5 Â 10 5 /kg (Table 3 ). In the multivariate analysis, the only variable that influenced myeloid engraftment was disease status at transplantation. This result was confirmed in an analysis that excluded the 16 children weighing o30 kg. The median time to neutrophil recovery was 24 days for patients transplanted in advanced phase and 18 days for those transplanted in a nonadvanced phase (Table 4) . Umbilical cord blood transplant in hematological malignancy J Sanz et al
Platelet engraftment
Eighteen patients died between 9 and 250 days after transplantation without platelet engraftment. The remaining 70 patients had platelet engraftment at a median time of 44 days (range, 17 --183). The CI of platelet engraftment was 80% at 183 days. The univariate analysis showed that the recipient's CMV serology, TNC number before freezing at a best cutoff of 4 Â 10 7 / kg and TNC number at infusion at a best cutoff of 3 Â 10 7 /kg had a significant impact on the CI of platelet recovery (Table 3 ). In the multivariate analysis, the only variable that influenced platelet recovery was the TNC dose at infusion at a best cutoff of 3 Â 10 7 / kg. The CI of platelet engraftment was 69 and 41 days for patients who received cord blood units below and above the best cutoff of 3 Â 10 7 TNCs/kg, respectively (Table 4) . and IV acute GVHD at day 100 after UCB transplantation was 24 and 13%, respectively. In univariate analysis, the variables that influenced the development of acute GVHD grade II --IV were age at a best cutoff of 20 years, weight at a best cutoff of 30 kg and TNC number before freezing at a best cutoff of 5 Â 10 7 /kg (Table 3 ). In the multivariate analysis, age was the only variable that remained significantly associated with acute GVHD grade II --IV. The CI of acute GVHD grade II --IV was 41 and 15% for patients o and 420 years, respectively (Table 4) .
One out of the eleven patients who developed acute GVHD grade III and IV is still alive. The TNC number before freezing at a best cutoff of 2 Â 10 7 /kg was associated with the development of acute GVHD grade III and IV in the univariate analysis ( Table 3 ). The CI of acute GVHD grade III and IV was 0 and 19% for patients who received cord blood units below and above 2 Â 10 7 /kg, respectively.
Chronic GVHD. In all, 29 out of the 70 at-risk patients developed chronic GVHD. Chronic GVHD was limited in 12 patients and extensive in 17 patients. The median time to the development of chronic GVHD was 137 days (range 65 --275). Four patients presented with chronic GVHD before day 100. The 5-year CI of overall and extensive chronic GVHD was 41 and 24%, respectively. Two patients died of chronic extensive GVHD.
In the univariate analysis, the variables that influenced the development of chronic extensive GVHD were body weight at a best cutoff of 60 kg and previous auto-SCT (Table 3) . Only previous auto-SCT remained significant in the multivariate analysis. The CI of chronic extensive GVHD was 45% for patients with a previous auto-SCT and 20% for those with no previous auto-SCT (Table 4) . NRM Thirty-nine transplant-related deaths occurred at a median time of 151 days after transplantation (range 9 --793). The CI of NRM at 100 days, 180 days and 5 years was 14, 23 and 44%, respectively (Figure 2 ). In the univariate analysis, the variables that influenced NRM were previous auto-SCT and HLA compatibility between the donor and recipient, considering typing at the low-resolution level, and low resolution for class I and high resolution for class II Ags (Table 3 ). In the multivariate analysis, previous auto-SCT and donor --recipient HLA compatibility with low-resolution techniques remained significantly associated with NRM. This result was confirmed in an analysis that excluded the 16 children weighing o30 kg. The CI of NRM at 5 years was 26% for patients who received cord blood units with a 4/6 Ag match compared with 61% for patients who received cord blood units with a 5/6 or 6/6 Ag match. Patients with previous auto-SCT had a CI of NRM at 5 years of 81% compared with 38% for those who did not ( Table 4) .
Causes of death
The causes of death were infection in 23 patients, relapse in 14, GVHD in 6 (four acute and two chronic), secondary malignancy in 5 (three with EBV-related posttransplant lymphoproliferative disorder and two with AML of donor origin), multiorgan failure in three, hemorrhage in one, primary graft failure in one and secondary graft failure in one. The etiologic agents of infections were nine bacterial infections, three CMV diseases, four aspergillosis, two CMV diseases with concomitant aspergillosis, two mycobacterium tuberculosis, one leishmaniasis, one toxoplasmosis and one BK virus leukoencephalopathy. The causes of death in patients with previous auto-SCT were infection in 10 patients, multiorgan failure in 2, relapse in 1 and EBV-related posttransplant lymphoproliferative disorder in 1. Distribution of causes of death was similar for patients who received cord blood units with a 4/6 Ag match compared with those who received cord blood units with a 5/6 or 6/6 Ag match.
Relapse
Fifteen patients relapsed at a median time of 6 months (range 1.5 --42). The 5-year CI of relapse was 18%. No factor was significantly associated with the relapse rate ( Figure 2 ). DFS Thirty-three patients remained alive and leukemia-free after UCB transplantation at the last follow-up (range 37 --74 months). The overall DFS at 5 years was 37% (95% confidence interval, 30 --44%).
In the univariate analysis, disease status, HLA mismatch at a lowresolution level and previous auto-SCT have a significant impact on DFS. In the multivariate analysis, disease status and HLA compatibility at a low-resolution level remained significantly associated with DFS. The DFS at 5 years was 46, 39 and 11% for patients transplanted in the early, intermediate and advanced phases of the disease, respectively (Figure 3) . The DFS at 3 years was 54 and 24% for patients who received UCB units with a 4/6 and 5/6 or 6/6 Ag match, respectively (Table 4) .
DISCUSSION
This study confirms that single-unit UCB transplantation from unrelated donors using BU-based myeloablative conditioning is a real alternative for patients for whom a hematopoietic SCT is indicated. This strategy enabled high rates of engraftment with fast neutrophil recovery in both children and adults. Transplantation in the early stage of the disease had a significantly higher probability of DFS. These data may provide clinically useful information to improve the outcome of UCB transplantation in patients with poor-risk hematological malignancies using a standardized strategy of cord blood unit selection and optimized conditioning regimen.
A limitation of our study is the inclusion of a heterogeneous series of patients in terms of diagnosis and age, although the patients received a homogeneous treatment strategy in terms of the conditioning regimen, GVHD prophylaxis and donor selection. Although the present study included both children and adults, most of the patients were adults (81%), and their ages were distributed evenly across the different decades of life. We noted that the results for the different outcomes evaluated did not differ when the pediatric population was excluded from the analysis. As usually seen in a series of alternative donor transplants, the patients included in the present study had underlying diseases with very poor prognosis defined by an advanced disease stage or, in those with less advanced disease, the presence of either unfavorable cytogenetics or other well-established high-risk features. It should be also noted that 18% of the patients in our series had been previously autografted. As discussed below, this condition affected negatively on NRM.
The median time to myeloid engraftment in the evaluable patients (all except one primary graft failure) compares favorably with that reported by other multicenter studies that included children 19 and adults, 20, 21 and with other reports using doublecord 3 or intrabone infusion. 6 We hypothesize that the conditioning regimen and the selection of the cord blood unit could explain these results. The addition of thiotepa and ATG to the combination of BU and fludarabine could have been crucial because use of this combination without addition of other agents produced disappointing results in terms of engraftment. 22 In contrast, the use of thiotepa and ATG produced a marked reduction in the rate of immunological rejection in patients given T-cell-depleted SCT from an HLA-identical sibling 23 or haploidentical donor. 24 When selecting the cord blood unit, maximizing the TNC dose was not considered the only goal for graft selection in this protocol. To optimize the selection, we also considered the CD34 þ cell dose, based on our previous studies showing that this factor was the most important predictor of myeloid and platelet engraftment. 25 When considering the strategies to improve engraftment, such as double-cord infusion, 3 direct intrabone transplantation 6 and ex vivo expansion, 5 future studies should assess their value by comparing them with optimized strategies with single-cord blood units as used in this study.
Our conditioning regimen had a 100-day NRM of 14%, which is within the lower range reported in the literature, 19 --21 except for a study from the University of Tokyo. 26 However, nonrelapse-related deaths caused by infection occurred later, with most in the first 18 months after transplantation. Infections were caused by a variety of microorganisms, similar to those typically seen in severely immunocompromised hosts. Interestingly, we observed the development of EBV-related posttransplant lymphoproliferative disorder in three patients and two other patients with AML of donor origin with monosomy 7. We noted that the previous auto-SCT had a strong negative impact on NRM with an unacceptable mortality of around 80%. Less intensive regimens should be explored for these patients. 27 Another factor that influenced NRM was the number of HLA disparities: a 4/6 HLA match was better than a 5/6 or 6/6 match. We have no definitive explanation for this apparently paradoxical finding. The statistical probability of error should always be considered with unexpected findings. However, one possible explanation may involve the association between TNC or CD34 þ cell dose and HLA compatibility. The percentage of 4/6 HLAmatched cord blood units with a TNC dose 43 Â 10 7 /kg was higher than those with a 5/6 or 6/6 HLA match (67% vs 40%; P ¼ 0.05). This is not surprising because more mismatched units are usually selected with higher cell content. Therefore, one should be cautious interpreting our results, but we can at least safely conclude that a two-Ag-mismatched graft does not imply an increased NRM.
The reason for the relatively low GVHD rate in the present series compared with the previously reported 28 remains unclear. Nevertheless, the use of rabbit ATG in the conditioning regimen may have contributed to this finding. With regard to the apparently paradoxical observation of an increased risk of acute GVHD grade II-IV in patients o20 years, a possible explanation may be related to the higher cell dose infused to pediatric patients. Nevertheless, a lower risk of GVHD in pediatric population has been consistently reported in the context of BM or PBSC transplantation, but not yet after UCB transplantation.
In conclusion, our study shows that a single-unit UCB transplantation from an unrelated donor after a myeloablative conditioning regimen based on i.v. BU, thiotepa, fludarabine and ATG results in high rates of engraftment with fast neutrophil recovery in both children and adults. Long-term DFS can be achieved in a substantial number of patients with high-risk hematological malignancies when transplanted in an early stage of the disease.
